Pharmaceutical News

RSS

Measles vaccine does not increase risk of autism in children, reveals Polish study

As a pivotal paper linking childhood vaccinations to autism is discredited, a new study finds no evidence that the measles vaccine—given alone or as part of a combined measles, mumps, and rubella (MMR) vaccine—increases the risk of autism in children. The study appears in The Pediatric Infectious Disease Journal (www.pidj.com), published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

10 Feb 2010

Researchers publish findings that may lead to new standard of care for cervical cancer patients

Researchers at the Ireland Cancer Center of University Hospitals (UH) Case Medical Center, have published new findings that may lead to a new standard of care for patients with locally advanced cervical cancer.

10 Feb 2010

Cholesterol lowering drugs also reduce risk of developing cataracts

Statins, a class of drugs used to lower cholesterol levels, have been successfully fighting heart disease for years. A new study from Tel Aviv University has now found that the same drugs cut the risks of cataracts in men by almost 40%.

10 Feb 2010

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses.

10 Feb 2010

Findings of poor quality malaria drugs in Africa add to artemisinin-resistance worries

A study released on Monday found that between 26 percent and 44 percent of artemisinin-based malaria drugs sold in Madagascar, Senegal and Uganda "failed quality testing" because of impurities or insufficient amounts of active ingredient, the Associated Press reports.

10 Feb 2010

MSU launches research and training program to address product counterfeiting

Michigan State University has launched the nation's first comprehensive research and training program designed to address product counterfeiting-- which the FBI has called "the crime of the 21st century."

10 Feb 2010

Research opens door for advancement of new category of painkillers

Research led by a scientist at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has opened the door for the advancement of a new category of painkillers, called TRPV1 antagonists.

10 Feb 2010

USPTO awards Transcept Pharmaceuticals patent covering Intermezzo's composition and usage method

Transcept Pharmaceuticals, Inc. today announced that the first patent covering the composition and method of use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office.

10 Feb 2010

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

A joint GA²LEN /EAACI report to be published in "Allergy" and available online on 8 February reviews new data on the treatment of allergies with older antihistamines compared with newer, second-generation H1-antihistamines. The research was funded by GA²LEN, an EU-funded Network of Excellence.

10 Feb 2010

Excelsior Medical receives Canadian marketing license for new, pre-filled catheter lock syringe

Excelsior Medical Corporation, one of the leading manufacturers of pre-filled catheter flush syringes, today announced that it has received a Medical Device License from Health Canada for its new, pre-filled catheter lock syringe to be sold in the Canadian marketplace.

10 Feb 2010

FDA expands indication for Crestor

On Feb. 8 the U.S. Food and Drug Administration approved the cholesterol-lowering medication Crestor (rosuvastatin) for some patients who are at increased risk of heart disease but have not been diagnosed with it.

10 Feb 2010

Morphologi G3 adds new dimension to Solvay Pharmaceuticals R&D

Solvay Pharmaceuticals Inc. (Marietta, GA, USA) was the first company in the United States to install the innovative Morphologi G3 image analysis-based particle characterization system from Malvern Panalytical.

From Malvern Panalytical 9 Feb 2010

Survey reveals need for better access to levalbuterol for asthma patients

A recent electronic survey of US asthma experts demonstrated the need for better access to levalbuterol, the fast-acting medicine used to treat the narrowing of airways (bronchospasm) caused by asthma, for selected patients.

9 Feb 2010

Regence introduces new solution that covers all medications under single medication benefit

Rapid developments in the pharmaceutical industry have led to a steady increase in the use and cost of "specialty" medications to treat chronic conditions such as arthritis and psoriasis.

9 Feb 2010

Cell Therapeutics' pixantrone NDA: FDA postpones ODAC meeting due to severe weather conditions

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.

9 Feb 2010

Merck's asthma drug formoterol/mometasone to garner global peak year sales of more than $250M

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected launch this year for the treatment of asthma, Merck's formoterol/mometasone will garner peak year sales of more than $250 million in the United States, France, Germany, Italy, Spain and the United Kingdom.

9 Feb 2010

FDA accepts Psyadon Pharmaceuticals' ecopipam IND for treatment of LND

Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.

9 Feb 2010

Glaucoma medications appear to reduce mortality risk

Glaucoma patients who take medication for the condition appear to have a reduced likelihood of death, according to a report in the February issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

9 Feb 2010

Study indicates pain treatment may vary in Latino and white children post surgery

Differences might exist in the amount of pain medicine given to Latino and white children after surgery, found a new, small study in which Latino children received 30 percent less opioid analgesics (morphine or morphine-like drugs) than white children did.

9 Feb 2010

FDA approves Lupin Pharmaceuticals' Amlodipine/Benazepril capsules

Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules. Commercial shipments of the product have already commenced.

9 Feb 2010

Pharmaceutical News

Measles vaccine does not increase risk of autism in children, reveals Polish study

Researchers publish findings that may lead to new standard of care for cervical cancer patients

Cholesterol lowering drugs also reduce risk of developing cataracts

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

Findings of poor quality malaria drugs in Africa add to artemisinin-resistance worries

MSU launches research and training program to address product counterfeiting

Research opens door for advancement of new category of painkillers

USPTO awards Transcept Pharmaceuticals patent covering Intermezzo's composition and usage method

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

Excelsior Medical receives Canadian marketing license for new, pre-filled catheter lock syringe

FDA expands indication for Crestor

Morphologi G3 adds new dimension to Solvay Pharmaceuticals R&D

Survey reveals need for better access to levalbuterol for asthma patients

Regence introduces new solution that covers all medications under single medication benefit

Cell Therapeutics' pixantrone NDA: FDA postpones ODAC meeting due to severe weather conditions

Merck's asthma drug formoterol/mometasone to garner global peak year sales of more than $250M

FDA accepts Psyadon Pharmaceuticals' ecopipam IND for treatment of LND

Glaucoma medications appear to reduce mortality risk

Study indicates pain treatment may vary in Latino and white children post surgery

FDA approves Lupin Pharmaceuticals' Amlodipine/Benazepril capsules

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News